-+ 0.00%
-+ 0.00%
-+ 0.00%

Enhua Pharmaceutical announced that the company recently obtained the “Drug Registration Certificate” for the chemical oxycodone hydrochloride sustained-release tablets approved and issued by the State Drug Administration. The specification is 10 mg. This drug is an anti-abuse sustained-release formulation independently developed by the company. It is used to treat severe pain that requires long-term continuous treatment with opioids every day. This approval adds a 10mg specification to the original 40mg specification, which can better meet patients' individualized dosage climbing needs, enrich the company's product pipeline in the field of central analgesics, and help enhance market competitiveness.

Zhitongcaijing·11/16/2026 07:57:08
Listen to the news
Enhua Pharmaceutical announced that the company recently obtained the “Drug Registration Certificate” for the chemical oxycodone hydrochloride sustained-release tablets approved and issued by the State Drug Administration. The specification is 10 mg. This drug is an anti-abuse sustained-release formulation independently developed by the company. It is used to treat severe pain that requires long-term continuous treatment with opioids every day. This approval adds a 10mg specification to the original 40mg specification, which can better meet patients' individualized dosage climbing needs, enrich the company's product pipeline in the field of central analgesics, and help enhance market competitiveness.